In its new annual edition, the US Off-Patent Drug Manufacturers Association offers a new estimate of the savings derived from the commercialization of US generic and biosimilar medicines in 2022. Regarding biosimilars, estimated savings of more than $23Bn and 694 million total days of patient treatment have been generated since its entry into the North American market in 2015.